All In Biotech

Drug Trial Radar · NCT00912925

Clinical Study of Aldurazyme in Patients With Mucopolysaccharidosis (MPS) I

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Multinational, Clinical Study of Recombinant Human Alpha L-Iduronidase In Patients With Mucopolysaccharidosis I

Last checked: Nov 20, 2026Latest source record: Apr 7, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

45

Actual

Start

Dec 2000

Primary completion

Sep 2001

Study completion Sep 2001

Sponsor

Lead sponsor
Genzyme, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
Collaborators
BioMarin/Genzyme LLC
First posted
Jun 3, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 5 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being conducted to demonstrate the safety and clinical efficacy of Aldurazyme treatment in MPS I patients

Conditions

  • Mucopolysaccharidosis I
  • Hurlers Syndrome
  • Hurler-Scheie Syndrome

Interventions

  • rhIDU (recombinant human-Alpha-L-Iduronidase)Biological

    Patients in the active treatment group received Aldurazyme intravenously at a dose of 100 units/kg (approximately 0.58mg/kg) administered intravenously over approximately 4 hours once weekly for 26 weeks.

  • PlaceboBiological

    Patients in the Placebo-control group were administered a solution of 100mM sodium phosphate , 150mM sodium chloride, and 0.001% polysorbate-80, adjusted to a pH of 5.8 administered intravenously over a time period of approximately 4 hours once weekly for 26 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Change From Baseline to Week 26 in Percent Predicted Forced Vital Capacity (FVC)Time frame: Baseline to Week 26
  2. Overall Change From Baseline to Week 26 in Six Minute Walk Test (6MWT)Time frame: Baseline to Week 26

Locations

4 sites in 3 countries. Site status is shown where the registry gives one.

  • Site not named

    New York, New York

  • Site not named

    Chapel Hill, North Carolina

  • Site not named

    Vancouver, British Columbia, Canada

  • Site not named

    Mainz, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.